Regenesance, developing novel treatments
for neurodegenerative disorders

  • bomen-home

First Therapeutic Product Focus

Regenesance is developing a line of products based on proprietary monoclonal antibodies to inhibit formation of the Membrane Attack Complex (MAC) part of the complement pathway.

Regenesance is focused on developing treatments for the orphan drug indications...

About us

Regenesance is a Dutch biotechnology company focusing on the development of novel therapeutic products for the treatment of neurological disorders, including Amyotrophic Lateral Sclerosis (ALS) and Myasthenia Gravis (MG).


June 2014

Regenesance antibody fully characterized and ready for production.

Spring 2014

Stichting ALS Nederland to invest in Regenesance and become a shareholder.